Fifth Third Bancorp Common Stock vs TransMedics Group Inc — how do they compare? Fifth Third Bancorp Common Stock trades at $50.25 (market cap $45.98B), while TransMedics Group Inc trades at $77.43 (market cap $2.74B). The key difference: Fifth Third Bancorp Common Stock is far larger — about 16.8× TransMedics Group Inc's market cap, and Fifth Third Bancorp Common Stock pays a 3.31% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fifth Third Bancorp Common Stock for 0 Days and TransMedics Group Inc for 24 Days on average.
| FITB | TMDX | |
|---|---|---|
Market Cap | $45.98B | $2.74B |
Volume | 10,522,320 | 949,331 |
Sector | Financials | Health |
52-Week High | $59.37 | $150.42 |
52-Week Low | $40.36 | $61.99 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $63.85B | $3.13B |
Dividend Yield | 3.31% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Fifth Third Bancorp provides retail and commercial banking, lending, payments, and wealth management services in the United States.
Read more on FITB →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →